NASH Market Research Report 2030

1. Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life- threatening condition called cirrhosis. NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms. DelveInsight's "Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Nonalcoholic Steatohepatitis (NASH) market report provides current treatment practices, emerging drugs, Nonalcoholic Steatohepatitis (NASH) market share of the individual therapies, current and forecasted Nonalcoholic Steatohepatitis (NASH) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Nonalcoholic Steatohepatitis (NASH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

2. Geographies covered are: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan Request for sample pages of our report: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis- nash-market Nonalcoholic Steatohepatitis (NASH) Disease Understanding and Treatment Algorithm The classification of fibrosis stages of NASH is as follows: No Fibrosis (F0), NASH Fibrosis (F1–F3), and NASH Cirrhosis (F4). According to various studies, such as Schuppan et al. (2018), Singh et al. (2014), and others, NASH has been defined to keep progressing from early stages (F0 and F1) to advanced stages (F2–F4) over time. The development of NASH with cirrhosis increases the risk of NASH Decompensated Cirrhosis and ultimately to death. The DelveInsight Nonalcoholic Steatohepatitis (NASH) market report gives a thorough understanding of the Nonalcoholic Steatohepatitis (NASH) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Diagnosis This segment of the report covers the detailed diagnostic methods or tests for Nonalcoholic Steatohepatitis (NASH). Treatment It covers the details of conventional and current medical therapies available in the Nonalcoholic Steatohepatitis (NASH) market for the treatment of the condition. It also provides Nonalcoholic Steatohepatitis (NASH) treatment algorithms and guidelines in the United States, Europe, and Japan. Nonalcoholic Steatohepatitis (NASH) Epidemiology The Nonalcoholic Steatohepatitis epidemiology division provide insights about historical and current Nonalcoholic Steatohepatitis (NASH)patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

3. Key Findings • Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH. These cases are expected to increase throughout the study period [2018–2030]. • We estimate the highest prevalence of NASH in the United States, accounting close to 50% of the total prevalent cases, followed by Japan. Download free sample pages of our report. Nonalcoholic Steatohepatitis (NASH) Drug Chapters Due to the unmet need for an approved therapy for the treatment of NASH, several companies have shifted their focus toward the development of targeted drugs with a novel mechanism of action. Key players in the market of NASH are Genfit, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira Therapeutics), Galmed Pharmaceuticals, Bristol-Myers Squibb, Cirius Therapeutics, Galectin Therapeutics, Immuron, NGM Biopharmaceuticals, Can-Fite BioPharma, Akcea Therapeutics, Oramed Pharmaceuticals, Ascletis, Terns Pharmaceuticals, Enyo Pharma, and others. We expect that the launch of emerging therapies will fill the void treatment areas shortly. The targeted therapies will have stronger penetration than the off-label therapies, and the market is expected to reach billions. Nonalcoholic Steatohepatitis (NASH) Market Outlook The market for the treatment of Nonalcoholic Steatohepatitis (NASH) is likely to experience significant annual growth over the 2018–2030 study period, as major-market sales are expected to increase by 2030. OCA is expected to grab maximum market share, owing to its development to target all stages of NASH (F1–F4), and with the increasing demand for therapies to treat the advanced stage of NASH, i.e., cirrhosis. The treatment of NASH depends on the stage of the disease. Currently, there is no approved therapy for the treatment of NASH, yet doctors prescribe certain off-label drugs (supportive therapies) for its management. Lifestyle modifications are, however, the first line of treatment. Lifestyle modifications include going for weight loss combined with an active exercise program along with a planned diet. Medications are then prescribed in the later stages when lifestyle modifications do not produce significant results. Insulin-sensitizing agents are prescribed in some

4. instances; however, metformin produced good results but temporarily, due to which it is not recommended much. Pioglitazone is suggested in select cases for patients already who have Type II diabetes. The Nonalcoholic Steatohepatitis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Nonalcoholic Steatohepatitis (NASH)markettrends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, Nonalcoholic Steatohepatitis (NASH) market in 7MM is expected to change in the study period 2017-2030.